Shots: The US FDA has permitted marketing of a device intended for the temporary reduction of sleep disturbance related to nightmares in patients aged ≥22 yrs. suffering from nightmare disorder […]readmore
Tags : Marketing
Shots: Medicure is responsible for the regulatory approval process for the product The agreement grants an exclusive right to Medicure to market & sell the product in the US, Canada […]readmore
Shots: Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan Additionally, Sun Pharma has acquired Pola Pharma and […]readmore
Shots: The P-III HERCULES study involves assessing Cablivi vs PBO in 145 patients with acquired thrombotic thrombocytopenic purpura (aTTP) in plasma exchange & immunosuppression P-III HERCULES study results: achievement in […]readmore
Shots: The approval is based on P-II TITAN and P-III HERCULES studies enrolling 220 adults assessing Cablivi (caplacizumab) vs PBO, testing its safety and efficacy P-III HERCULES results: significantly shorter […]readmore
Shots: First and only therapy approved for LD patients with confirmed or acquired in adults and children ≥2yrs; partial or acquired LD in adults or children ≥12yrs in Europe after […]readmore